AMNEAL PHARMACEUTICALS INC CLASS A (AMRX) competitors & alternatives
Health Care · NASDAQ
AMNEAL PHARMACEUTICALS INC CLASS A (AMRX)'s top competitors and alternatives — its most similar public companies — include Viatris (VTRS), ANI PHARMACEUTICALS INC (ANIP), McKesson Corporation (MCK), Cardinal Health (CAH), Amgen (AMGN), UROGEN PHARMA LTD (URGN), OCULAR THERAPEUTIX INC (OCUL), XERIS BIOPHARMA HOLDINGS INC (XERS), RELMADA THERAPEUTICS INC (RLMD), WHITEHAWK THERAPEUTICS INC (WHWK), AMPHASTAR PHARMACEUTICALS INC (AMPH) and COLLEGIUM PHARMACEUTICAL INC (COLL). These are AMNEAL PHARMACEUTICALS INC CLASS A's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top AMRX competitors & alternatives
-
ViatrisVTRSHealth Care
A global pharmaceutical giant supplying over 1 billion patients annually with generics, branded medicines, and an expanding innovative pipeline across more…
$17.28 (as of 2026-07-23) · market cap $20.1B
-
ANI PHARMACEUTICALS INCANIPHealth Care
A diversified biopharmaceutical company focused on growing its Rare Disease, Brands, and Generics segments through a combination of internal development and…
$78.53 (as of 2026-07-23) · market cap $1.8B
-
McKesson CorporationMCKHealth Care
McKesson is a healthcare services giant that orchestrates the entire pharmaceutical and medical supply chain—from drug distribution and specialty oncology care…
$824.49 (as of 2026-07-23) · market cap $96.0B
-
Cardinal HealthCAHHealth Care
Cardinal Health is a healthcare services and logistics company that distributes pharmaceuticals, medical supplies, and healthcare IT solutions to pharmacies,…
$225.98 (as of 2026-07-23) · market cap $52.4B
-
AmgenAMGNHealth Care
A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone…
$371.50 (as of 2026-07-23) · market cap $195.9B
-
UROGEN PHARMA LTDURGNHealth Care
UroGen Pharma is transforming the treatment of urothelial cancers with its proprietary hydrogel technology that allows for non-surgical, sustained-release drug…
$42.50 (as of 2026-07-23) · market cap $2.1B
-
OCULAR THERAPEUTIX INCOCULHealth Care
Ocular Therapeutix is a biopharmaceutical company leveraging proprietary bioresorbable hydrogel technology to deliver retinal therapies, with AXPAXLI…
$8.62 (as of 2026-07-23) · market cap $1.9B
-
XERIS BIOPHARMA HOLDINGS INCXERSHealth Care
A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug…
$8.41 (as of 2026-07-23) · market cap $1.5B
-
RELMADA THERAPEUTICS INCRLMDHealth Care
Clinical-stage biotech redirecting toward oncology and neurology with in-licensed chemotherapy delivery and neurosteroid platforms after terminating its lead…
$5.20 (as of 2026-07-23) · market cap $538M
-
WHITEHAWK THERAPEUTICS INCWHWKHealth Care
Clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens with advanced linker-payload…
$3.83 (as of 2026-07-23) · market cap $220M
-
AMPHASTAR PHARMACEUTICALS INCAMPHHealth Care
Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging…
$18.87 (as of 2026-07-23) · market cap $851M
-
COLLEGIUM PHARMACEUTICAL INCCOLLHealth Care
A specialty pharma company building a diversified pain and ADHD portfolio through branded products and acquisitions, though facing material generic headwinds…
$35.59 (as of 2026-07-23) · market cap $1.2B
Not quite? Describe exactly what you want →
Peers are AMNEAL PHARMACEUTICALS INC CLASS A's closest public companies by shared sub-industry, sector and business themes. See the full profile: AMNEAL PHARMACEUTICALS INC CLASS A (AMRX).
Last updated 2026-07-23.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.